Business Wire

FlowMetric Europe Headquarters Moves to Zambon OpenZone Campus

Del

FlowMetric Europe, a wholly owned subsidiary of FlowMetric Life Sciences, is excited to announce that it will be opening its expanded European Headquarters office within the OpenZone campus (www.openzone.it), effective January 28th, 2019. The OpenZone scientific campus, a center of excellence for research and innovation located in Bresso, Italy is fully dedicated to the Life Sciences, has over 7,500 square meters of laboratory space, and hosts 22 companies focused on the biotechnology, pharmaceutical, and advanced gene therapy fields.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190108005310/en/

The new FlowMetric Europe Headquarters will be located within the Zambon OpenZone Campus at Via Anto ...

The new FlowMetric Europe Headquarters will be located within the Zambon OpenZone Campus at Via Antonio Meucci, 3, 20091 BRESSO (MI), a short distance from Milan center city. (Photo: Business Wire)

Mr. Renold Capocasale, founder and CEO of FlowMetric Life Sciences, is thrilled about the move and commented that "our global business has grown quickly and by relocating to a scientifically innovative and vibrant campus dedicated to the Life Sciences, while also increasing our office and lab space, will allow us to continue to grow our successful full-service flow cytometry CRO."

The new headquarters, containing three laboratories and offices, will be equipped with high dimensional flow cytometry instruments as well as a full tissue culture suite, in order to provide quality flow cytometry and cell sorting services to FlowMetric Europe’s European clients in the preclinical and clinical phases of development.

“We have a strong team here in Italy, true experts and industry leaders in the flow cytometry field,” notes Mr. Gianluca Carenzo, Vice President of FlowMetric Europe. “This move and expansion is necessary to support our continued client requests for additional global clinical trials in the EU.”

The FlowMetric Europe facilities will be located at Via Antonio Meucci, 3, 20091 BRESSO (MI), a short distance from Milan center city.

About FlowMetric Life Sciences

The FlowMetric Life Sciences family of companies is driven to provide Flow Cytometry Solutions in Precision Medicine. FlowMetric and FlowMetric Europe are a full service Flow Cytometry and Cell Sorting contract research organization. The company provides services for global partners in multiple therapeutic areas as well as throughout every phase of pharmaceutical development (preclinical research, non-GLP and GLP Toxicology studies as well as Clinical Phase 0-IV trials). Building on a combined 100 years of expertise in flow cytometry and advanced analysis platforms, FlowMetric Life Sciences adds value across the spectrum of drug discovery, translational research and clinical trials.

About OpenZone

OpenZone is a campus dedicated to Life Sciences created by Zambon to perform research in an approach based on open innovation. Conceived with the mission of creating an entrepreneurial ecosystem to promote the exchange of knowledge and give rise to collaborations, the campus now accommodates over 20 companies, including some of the leading biotech, pharmaceutical and advanced gene therapy companies that are strongly oriented towards research and innovation, with internationally known and qualified experts. Thanks to an investment of 60 million Euros, OpenZone will double the existing space and number of laboratories by 2020, to a total area of 37,000 square meters that will provide space for up to 1,200 people.

Contact information

FlowMetric Life Sciences
Rachel Bunting, MS, MBA
VP, Global Sales & Marketing
RBunting@flowmetric.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Fishawack continues to build best-in-class service offering with Dudnyk acquisition20.3.2019 13:00:00 CETPressemelding

Fishawack, a leading independent healthcare communications specialist, is excited to announce its acquisition of Dudnyk, the Philadelphia-based healthcare communications agency. Dudnyk is an award-winning, full-service agency that specializes in creating insight-driven, authentic brand experiences that unite specialty physicians and their patients. They leverage strategic, scientific, and creative capabilities to serve clients in the biotech, pharmaceutical, and medical device industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190320005204/en/ Dudnyk leadership team includes Christopher Tobias, PhD, President; Laurie Bartolomeo, EVP, Creative Director; Drew Desjardins, EVP, Chief Strategy Officer; Annemarie Armstrong, EVP, Director of Client Services; John Kemble, EVP, Creative Producer. (Photo: Business Wire) Fishawack’s goal is to increase the range of healthcare communications services that it can offer to commerc

ExaGrid Nominated in Six Categories for the 2019 Network Computing Awards20.3.2019 12:00:00 CETPressemelding

ExaGrid ®, a leading provider of intelligent hyperconverged storage for backup, today announced that it has been nominated in six categories for the 2019 Network Computing Awards. ExaGrid has become a finalist for Data Centre Product of the Year, The Return on Investment Award, Hardware Product of the Year, Product of the Year, The Customer Service Award, and Company of the Year. Voting to determine the winner in each category is underway now and closes on April 23. The results will be revealed at an evening award ceremony in London on May 2. ExaGrid’s model EX63000E backup storage appliance with data deduplication is a nominee in four categories. The model provides the largest scale-out system and offers up to a 2PB full backup with an ingest rate of 432TB/hr, which is three times faster than any other backup storage on the market. “We are thrilled to be nominated by IT staff, and recognized by Network Computing, in six prestigious categories this year,” said Bill Andrews, CEO and Pre

Eos Biosciences Issued Patent for New Approach to Shuttle Therapeutics Across the Blood-Brain Barrier to Treat Brain Diseases20.3.2019 11:30:00 CETPressemelding

Eos Biosciences, Inc. (Eos), a nanomedicines company developing an efficient and versatile nanobiologic particle-based platform technology (Eosomes), announced that the U.S. Patent and Trademark Office has granted Eos Biosciences Patent No. 10,183,078, relating to a novel approach of using HER3-targeted Eosomes as a shuttle system for transporting various classes of therapeutics across the blood-brain barrier for treatment of brain disorders, including brain cancer. The patent is owned by Cedars-Sinai Medical Center and is exclusively licensed to Eos Biosciences. Details of the system will be highlighted in an upcoming manuscript from Lali Medina-Kauwe, PhD, Professor, Department of Biomedical Sciences, Cedars-Sinai. Omar Haffar, Ph.D., Founder, President and Chief Executive Officer, commented, “We’re very excited by the issuance of this pivotal patent and look forward to receiving similar approvals in other countries. This patent adds to Eos’ considerable IP portfolio covering the Eos

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics20.3.2019 10:45:00 CETPressemelding

Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that Pfizer has acquired a 15% equity interest in Vivet and secured an exclusive option to acquire all outstanding shares. Pfizer and Vivet will collaborate on the development of VTX-801, Vivet’s proprietary treatment for Wilson disease. Wilson disease is a devastating, rare, chronic, and potentially life-threatening liver disorder of impaired copper transport that causes serious copper poisoning. In patients with Wilson disease, a monogenetic mutation disables the normal copper biliary excretion pathway leading to excess copper accumulation in the liver and other organs including the central nervous system. Untreated, Wilson disease results in various combinations and severity of hepatic (fibrosis and cirrhosis), neurologic and psychiatric symptoms, which can b

Fintech Company Rimilia Appoints Kevin Kimber as CEO20.3.2019 10:00:00 CETPressemelding

Rimilia, a fintech company helping finance departments simplify the complex, has appointed Kevin Kimber as CEO. The news follows another strong year for Rimilia. In 2018, Rimilia opened offices in Central London and Denver, Colorado in the U.S., and reported significant revenue growth on the previous year. Rimilia was founded in 2008 and its platform, created by finance professionals, uses RPA (robotic process automation) technology to help finance teams fast-track their cash flow by providing clearer information and better control. It has quickly become the industry leader, trusted by a number of global brands from HSBC to DHL and Santander, to provide visibility, improve efficiencies and guarantee cash flow. Rimilia works with any currency, any bank and in any language, and on average delivers 70% cost-savings and an 80% reduction in manual effort to its customers. Kevin joins Rimilia from Eight Roads Ventures (one of Rimilia’s investors), where he was a Venture Partner, advising its

Knopp Biosciences Enters Collaboration with Leading UK Investigators to Commence Phase 2 Clinical Trial of Dexpramipexole in Severe Eosinophilic Asthma20.3.2019 10:00:00 CETPressemelding

Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet need, today announced a collaboration with a consortium of leading medical researchers in the United Kingdom to evaluate the ability of Knopp’s lead drug candidate, dexpramipexole, to reduce exacerbations in people with severe eosinophilic asthma. The project is chiefly funded by the National Institute for Health Research (NIHR) and Medical Research Council (MRC) of the UK. The Chief Investigator for the Phase 2 multi-center, 52-week trial is Professor Salman Siddiqui, Professor of Airway Diseases at the University of Leicester and Consultant Respiratory Physician at Leicester’s Hospitals. Dexpramipexole is an orally available small molecule shown to selectively reduce eosinophil levels in multiple clinical trials, including in a Phase 2 study in hypereosinophilic syndrome (HES) and a Phase 2 trial in chr